Novavax, Inc. (NVAX)
Current
- (-)
After Hours
Rating Performance
Rating Return
+0.0% vs
Rating Accuracy
0.0% (0 of 0*)
Rating Return
+0.0% vs
Rating Accuracy
0.0% (0 of 0*)
Rating Return
-16.97% vs
Rating Accuracy
0.0% (0 of 1*)
Rating Return
-0.26% vs
Rating Accuracy
66.67% (2 of 3*)
FV Performance
FV Accuracy
0 Hits (0.0% Hit Rate)
FV Avg. Distance
+293.56%
FV Accuracy
0 Hits (0.0% Hit Rate)
FV Avg. Distance
+293.56%
FV Accuracy
0 Hits (0.0% Hit Rate)
FV Avg. Distance
+261.81%
FV Accuracy
5 Hits (10.2% Hit Rate)
FV Avg. Distance
+111.3%
About
CEO
Stanley C. Erck
Employees
165
Industry
Infectious Disease Biopharmaceuticals
Sector
Healthcare
Headquarters
Gaithersburg
Exchange
NASDAQ
Website
http://www.novavax.comSummary Stats
Market Cap
4.05B
Revenue
1.4B
Net Income
-1.32B
EPS
-$17.26
Price-to-Earnings
-3.0
Price-to-Book
61.97
Debt-to-Equity
42.4
News
Analyst Ratings
Price targets projected by 5 analysts
High
$223.00
Average
$186.20
Low
$75.00
Ratings calculated by 6 analysts
Buy
4
Hold
1
Sell
1
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q1 2022
Missed by -$0.13
$2.56 -4.8%
2.69
-3.05
Up 183%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--